• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Introduction to 2-Methyl-2H-indazole-6-carboxylic acid (CAS No. 1031417-46-5)

2-Methyl-2H-indazole-6-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1031417-46-5, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the indazole class, characterized by a fused benzene and pyrrole ring system, with a methyl group and a carboxylic acid substituent at specific positions. The unique structural features of 2-Methyl-2H-indazole-6-carboxylic acid make it a promising scaffold for the development of novel bioactive molecules.

The indazole moiety is a privileged structure in drug discovery, exhibiting a wide range of biological activities due to its ability to interact with various biological targets. The presence of the carboxylic acid group at the 6-position introduces additional functionalization possibilities, allowing for further derivatization to enhance pharmacological properties. This compound has been studied for its potential applications in the synthesis of inhibitors, modulators, and other therapeutic agents.

In recent years, there has been a surge in research focused on indazole derivatives due to their demonstrated efficacy in various disease models. Specifically, 2-Methyl-2H-indazole-6-carboxylic acid has been explored for its role in modulating enzyme activity and receptor interactions. For instance, studies have indicated that derivatives of this compound may exhibit inhibitory effects on certain kinases and transcription factors, which are implicated in cancer progression and inflammatory diseases.

The carboxylic acid functionality of 2-Methyl-2H-indazole-6-carboxylic acid (CAS No. 1031417-46-5) allows for salt formation, which can improve solubility and bioavailability—critical factors in drug formulation. This property has been leveraged in preclinical studies where the compound has been incorporated into prodrugs or conjugates to enhance delivery systems. Additionally, the methyl group at the 2-position contributes to steric hindrance, influencing binding affinity and selectivity when designing small-molecule inhibitors.

Advances in computational chemistry and high-throughput screening have accelerated the discovery of novel indazole-based compounds. Virtual screening methods have identified 2-Methyl-2H-indazole-6-carboxylic acid as a hit compound in several target-based assays, prompting further experimental validation. Researchers have employed structure-activity relationship (SAR) studies to optimize analogs of this scaffold, aiming to improve potency and reduce off-target effects.

The synthesis of 2-Methyl-2H-indazole-6-carboxylic acid involves multi-step organic transformations, including cyclization reactions and functional group interconversions. Recent methodologies have focused on greener synthetic routes, utilizing catalytic systems that minimize waste and energy consumption. Such approaches align with the growing emphasis on sustainable practices in pharmaceutical manufacturing.

In clinical contexts, derivatives of indazoles have shown promise in treating neurological disorders, cardiovascular diseases, and infectious diseases. While 2-Methyl-2H-indazole-6-carboxylic acid itself may not be directly used therapeutically at this stage, its structural motifs have inspired the development of lead compounds that are currently undergoing preclinical evaluation. The compound’s role as an intermediate in drug synthesis underscores its importance in medicinal chemistry pipelines.

Future research directions may explore the pharmacokinetic properties of 2-Methyl-2H-indazole-6-carboxylic acid (CAS No. 1031417-46-5) to better understand its metabolic fate and potential side effects. Techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy are being employed to characterize metabolites and interactions with biological matrices. These studies will provide critical data for optimizing drug candidates derived from this scaffold.

The versatility of 2-Methyl-2H-indazole-6-carboxylic acid as a building block for drug discovery continues to drive innovation in synthetic chemistry. Its integration into libraries of diverse compounds ensures that it remains a valuable asset for academic researchers and pharmaceutical companies alike. As our understanding of biological pathways evolves, new opportunities for leveraging this compound’s unique structural features will emerge.

• 1092351-86-4(Methyl 2-methyl-2H-indazole-5-carboxylate)
• 1071433-06-1(2-methyl-2H-indazole-4-carboxylic acid)
• 1071428-43-7(Methyl 2-methyl-2H-indazole-4-carboxylate)
• 1071428-42-6(Methyl 1-methyl-1H-indazole-4-carboxylate)
• 1092351-82-0(Methyl 1-methyl-1H-indazole-5-carboxylate)
• 1234615-75-8(2-methyl-2H-indazole-7-carboxylic acid)
• 1031417-77-2(1-Methyl-1H-indazole-6-carboxylic acid)
• 1071433-01-6(Methyl 2-methyl-2H-indazole-6-carboxylate)
• 1176754-31-6(1-Methyl-1H-indazole-5-carboxylic acid)
• 1007219-73-9(Methyl 1-methyl-1H-indazole-6-carboxylate)